Plné znění - 36/2019 Sb. m. s.

Sdělení o přijetí nového znění Přílohy I (Seznam zakázaných látek a metod dopingu pro rok 2018 - Mezinárodní standard)

36/2019 Sb. m. s.

Sdělení

INFORMACE

36

XXXXXXX

Xxxxxxxxxxxx zahraničních xxxx,

xxxxxx xx mění x xxxxxxxx sdělení Ministerstva xxxxxxxxxxxx xxxx č. 58/2007 Sb. m. x. x x. 46/2008 Sb. x. x.

Xxxxxxxxxxxx xxxxxxxxxxxx xxxx xxxxxxx, xx xxx 1. xxxxx 2017 xxxx xxxxxxxxx ředitelkou XXXXXX xxxxxxxx xxxxxxxxx xxxxxx znění Xxxxxxx X - Xxxxxx xxxxxxxxxx xxxxx x xxxxx dopingu xxx xxx 2018 - Xxxxxxxxxxx standard Xxxxxxxxxxx xxxxxx xxxxx xxxxxxx xx xxxxxx¹⁾.

X xxxxx xxxxxx Přílohy X xxxxxxxx xxxxxxx Xxxxxxxxx Xxxxx xxxxxxxxx x xxxxxxxxx xxxxxxxxx podepsal xxxxxxx x xxxxxxx xxxx Přílohy X Xxxxxx xxxxxxxxxx.

Xxxx znění Xxxxxxx X xxxxxxxxx x xxxxxxxx v xxxxxxx x článkem 34 xxxx. 3 Úmluvy xxx 1. xxxxx 2018. Xxx Xxxxxx xxxxxxxxx xxxxxxxxx nové xxxxx Přílohy I x xxxxxxxx dne 5. června 2019.

Dnem xxxxxx xxxxxx xxxxx Xxxxxxx X x xxxxxxxx xxxxxxxx xxxxxx xxxxx Přílohy I xxxxxx od 1. xxxxx 2017 x xxxxxxxxx pod č. 80/2017 Sb. m. s.

Anglické xxxxx nového znění Xxxxxxx X x xxxx xxxxxxx do xxxxxxx jazyka xx xxxxxxxxx xxxxxxxx.

XXXXXXX

XXXXXXXXXXXXX

XXXXXXXX

XXXXXXX XXXXXXXXXXXXX XXXXX

XXXXXX XXXXXXXXXX XXXXX X XXXXX XXXXXXX XXX ROK 2018

XXXXXXXXXXX XXXXXXXX

Xxxxxxxxx xxxx Seznamu xxxx spravován WADA x xxxx xxxxxxxxxx x xxxxxxxxxx a xxxxxxxxxxxxx.

X případě xxxxxxxxxxx xxxxxxxxx xxxx anglickou x francouzskou xxxxx xxxx xxxxxxxxxxx anglická xxxxx.

Xxxxx Xxxxxx xxxx xxxxxx xx 1. xxxxx 2018 

SEZNAM ZAKÁZANÝCH XXXXX X XXXXX XXXXXXX PRO XXX 2018

XXXXXXX ANTIDOPINGOVÝ XXXXX

Xxxxxx xx 1. xxxxx 2018

XXXXX X XXXXXX XXXXXXXX STÁLE (PŘI XXXXXXX X XXXX XXXXXX)

Xxxxx xxxxxx 4.2.2 Xxxxxxxxx xxxxxxxxxxxxxxx xxxxxx všechny Xxxxxxxx látky budou xxxxxxxxxx xx "Xxxxxxxxxx xxxxx" kromě látek xx skupin S1, X2, X4.4, S4.5 x X6(x) x Xxxxxxxxxx xxxxx X1, X2 x M3.

ZAKÁZANÉ XXXXX

X0. NESCHVÁLENÉ XXXXX

Xxxxxxxxx xxxxxxxxxxxxx xxxxx, xxxxx xxxx zahrnuta x xxxxxxxxxxxxx xxxxxxx Seznamu x xxxx aktuálně xxxxxxxxx xxx humánní xxxxxxxxxxxx použití xxxxxxxxxx xxxxxxx xxxxxxxxxxxxx xxxxxxxxxx xxxxxx (xxxx. xxxxxx x preklinickém xxxx xxxxxxxxx stadiu výzkumu xxxx xx xxxxxxxx xxxxxxxxxx, xxxxxxxxxx xxxxx, xxxxx xxxxxxxxx xxxxx xxx xxxxxxxxxxx použití), xx zakázána xxxxx.

X1. XXXXXXXXXX XXXXX

Xxxxxxxxxx látky xxxx xxxxxxxx.

1. XXXXXXXXXX XXXXXXXXXX STEROIDY (XXX):

(x) Xxxxxxxx* XXX, xxxxxxxxxx:

1-xxxxxxxxxxxxx (5α-xxxxxxx-1-xx-3ß,17ß-xxxx);

1-xxxxxxxxxxxxx (5α-xxxxxxx-1-xx-3,17-xxxx);

1-xxxxxxxxxxx (3α-xxxxxxx-5α-xxxxxxx-1-xx-17-xx);

xxxxxxxxx (xxxx-4-xx-3ß, 17ß-xxxx);

xxxxxxxxxx;

xxxxxxx ([1,2]xxxxxxx[4',5':2,3]xxxxxx-4-xx-20-xx-17α-xx);

xxxxxxxxxxxxxxxxxxxxxxxxxxxxx (4-xxxxxx-17ß-xxxxxxx-17α-xxxxxxxxxxxxxx-1,4-xxxx-3-xx);

xxxxxxxxxxxxxxxxxxxxxxx (17α-methyl-5α-androst-2-en-17ß-ol);

drostanolon;

ethylestrenol (19-norpregna-4-en-17α-ol);

fluoxymesteron;

formebolon;

furazabol (17α-xxxxxx[1,2,5]xxxxxxxxxx[3',4':2,3]-5α-xxxxxxxxx-17ß-xx);

xxxxxxxxx;

4-xxxxxxxxxxxxxxxxxx (4,17ß-xxxxxxxxxxxxxxxx-4-xx-3-xx);

xxxxxxxxxx;

xxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxxxx (17ß-xxxxxxx-17α-xxxxxxxxxxxxxx-1,4-xxxx-3-xx);

xxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxxx (17ß-xxxxxxx-2α,17α-xxxxxxxx-5α-xxxxxxxxx-3-xx);

xxxxxxxxxxxxxx (17ß-xxxxxxx-17α-xxxxxxxxxxx-4,9-xxxx-3-xx);

xxxxxx-1-xxxxxxxxxxx (17ß-hydroxy-17α-methyl-5α-androst-1-en-3-on);

methylnortestosteron (17ß-xxxxxxx-17α-xxxxxxxxxx-4-xx-3-xx);

xxxxxXxxxxxxxxxxx;

xxxxxxxxxx (xxxxxxxxxxxxxxx (17ß-hydroxy-17α-methylestra-4,9,11-trien-3-on);

miboleron;

norboleton;

norethandrolon;

norklostebol;

oxabolon;

oxandrolon;

oxymesteron;

oxymetolon;

prostanozol (17ß-[(xxxxxxxxxxxxxxx-2-xx)xxx]-1’X-xxxxxxxx[3,4:2,3]-5α-xxxxxxxxxx);

xxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxx;

1-xxxxxxxxxxx (17ß-xxxxxxx-5α-xxxxxxx-1-xx-3-xx);

xxxxxxxxxxxxxxxxxxx (17-xxxxxxx-18α-xxxx-19-xxx-17α-xxxxxx-4,9,11-xxxxx-3-xx);

xxxxxxxxx (17ß-xxxxxxxxxxx-4,9,11-xxxxx-3-xx);

x xxxxx látky x xxxxxxxx xxxxxxxxx xxxxxxxxxx xxxx podobnými xxxxxxxxxxxx účinky.

b. Xxxxxxxxx** XXX, xxxxx xxxx xxxxxx xxxxxxxx:

Xxxxxxxxxxxxx (5α-xxxxxxxxxxxxxxxxxx, 17ß-xxxxxxx-5α-xxxxxxxxx-3-xx);

xxxxxxxxxxxxx (androst-5-en-3ß,17ß-diol);

androstendion (xxxxxxx-4-xx-3,17-xxxx);

xxxxxxxx;

xxxxxxx (xxxxxxxx-1,4-xxxx-3,17-xxxx);

xxxxxxxxx;

19-xxxxxxxxxxxxxxxx (estr-4-en-3,17-diol);

19-norandrostendion (estr-4-en-3,17-dion);

prasteron (xxxxxxxxxxxxxxxxxxxxx, XXXX, 3ß-xxxxxxxxxxxxxx-5-xx-17-xx);

xxxxxxxxxxx;

x xxxxxx xxxxxxxxxx a xxxxxxx, xxxxxx, xxx xx x xxxxxxxx xxxxx na ně:

5α-androstan-3α,17α-diol;

5α-androstan-3α,17ß-diol;

5α-androstan-3ß,17α-diol;

5α-androstan-3ß,17ß-diol;

5ß-androstan-3α,17ß-diol;

5α-androst-2-en-17-on;

androst-4-en-3α,17α-diol;

androst-4-en-3α,17ß-diol;

androst-4-en-3ß,17α-diol;

androst-5-en-3α,17α-diol;

androst-5-en-3α,17ß-diol;

androst-5-en-3ß,17α-diol;

4-androstendiol (xxxxxxx-4-xx-3ß,17ß-xxxx);

5-xxxxxxxxxxxxx (xxxxxxx-5-xx-3,17-xxxx);

xxxxxxxxxxx;

xxx-xxxxxxxxxxxxxxxxxx;

xxxxxxxxxxxxxx;

xxxxxxxxxxxxxx;

3ß-xxxxxxx-5α-xxxxxxxxx-17-xx;

7α-xxxxxxx-XXXX;

7ß-xxxxxxx-XXXX;

7-xxxx-XXXX;

19-xxxxxxxxxxxxxx;

19-xxxxxxxxxxxxxxxxx.

2. Ostatní xxxxxxxxxx látky, zahrnující:

Klenbuterol; xxxxxxxxxx xxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxx (XXXX, xxxx. xxxxxxx, XXX-4033, xxxxxxx x XXX140); xxxxxxx; xxxxxxx a xxxxxxxxxx, xxx ne x xxxxxxxx xxxxx na xx.

Xxx xxxxx xxxxxxx xxxx xxxxx: * "exogenní" xx xxxxxxxx x xxxxx, kterou xxxx xxxxxxxx xxxxxxxxx xxxxxxxxxxx. ** "xxxxxxxxx " xx xxxxxxxx k látce, xxxxxx xxxx xxxxxxxx xxxxxxxxx xxxxxxxxx.

X2. XXXXXXXXX XXXXXXX, XXXXXXX XXXXXXX, XXXXXXXX XXXXX A XXXXXXXX

Xxxxxxxxxxx látky a xxxxx xxxxx s xxxxxxxx xxxxxxxxx xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxx xxxxxx xxxx zakázány:

1. Xxxxxxxxxxxxx (EPO) a xxxxxxxxxx xxxxxxxxxxx erytropoézu, xxxxxx, xxx ne x xxxxxxxx pouze xx xx:

1.1 Xxxxxxxx xxxxxxxxxxxxxxxxx receptoru, xxxx

xxxxxxxxxxxx (xXXX); xxxxxxxxxxxxx (XXX); xxxxxxxxxx xxxxxxxx xx XXX (XXX-Xx, xxxxxxxxxxxxxxxxxxxxxxxx-xxxxxxx xxxx (XXXX)); XXX-xxxxxxxxx xxxxxxxxxx x jejich xxxxxxxxxx (xxxx. CNTO 530 a xxxxxxxxxxx).

1.2 Xxxxxxxxx prostředky xxxxxxx xxxxxxxxxxxxxx faktoru (HIF), xxxx.

xxxxx; xxxxxx; molidustat; xxxxxxxxxx (XX-4592); xxxxx.

1.3 Xxxxxxxxxx XXXX, xxxx.

X-11706.

1.4 Xxxxxxxxxx TGF - xxxx (XXX - β), např.

luspatercept; sotatercept.

1.5 Xxxxxxxx xxxxxxxxx xxxxxxxxx xxxxxxxxx. např.

asialo XXX; xxxxxxxxxxxxx XXX.

2. Xxxxxxxxx xxxxxxx x hormonové xxxxxxxxxx

2.1 Xxxxxxxxxxxxxxxxxx (CG) x xxxxxxxxxxxx xxxxxx (XX) x xxxxxx xxxxxxxxxx xxxxxxx, xxxx. xxxxxxxxx, deslorelin, gonadorelin, xxxxxxxxx, xxxxxxxxxxx, xxxxxxxxx x xxxxxxxxxxx, x xxxx.

2.2 Kortikotropiny x xxxxxx xxxxxxxxxx xxxxxxx, xxxx. kortikorelin.

2.3 Xxxxxxx xxxxxx (XX), xxxx xxxxxxxxx x xxxxxxxxxx xxxxxxx, xxxxxx, ale xx x omezením xxxxx xx ně:

fragmenty xxxxxxxxx xxxxxxx, xxxx. XXX-9604 x xXX 176-191; xxxxxx xxxxxxxxxx xxxxxxx xxxxxx (XXXX) x xxxx analoga, xxxx. CJC-1295, sermorelin x xxxxxxxxxxx; xxxxxxxxxxx xxxxxxxxx xxxxxxx (GHS), xxxx. ghrelin x xxxxxxxx xxxxxxxx, např. xxxxxxxxxx, ipamorelin a xxxxxxxxxxx; uvolňující xxxxxxx xxxxxxxxx hormonu (GHRP), xxxx. xxxxxxxxxxxx, GHRP-1, XXXX-2 (xxxxxxxxxxx), XXXX-3, XXXX-4, GHRP-5, GHRP-6 x xxxxxxxxx.

3. Xxxxxxx xxxxxxx x xxxxxxxxxx xxxxxxxxx xxxxxxx, xxxxxx, xxx ne x xxxxxxxx xxxxx xx xx:

xxxxxxxxxxxxx růstové xxxxxxx (XXXx);

xxxxxxxxxxxx xxxxxxx xxxxxx (XXX);

xxxxxxxx podobný xxxxxxx xxxxxx-1 (XXX-1) a xxxx xxxxxxx

xxxxxxxxxx xxxxxxx xxxxxxx (XXX);

xxxxxxx faktor xxxxxxxx z xxxxxxxx xxxxxxxx (PDGF);

thymosin- β4 x jeho xxxxxxxx, xxxx. XX-500;

xxxxxxxxxx-xxxxxxxxxxxx xxxxxxx xxxxxx (XXXX).

Xxxxx xxxxxxx xxxxxxx x xxxxxxxxxx xxxxxxxxx xxxxxxx xxxxxxxxxxx xxxxxxx nebo degradaci xxxxxxxx svalů, xxxxx x xxxxxx, xxxxxx xxxxxxxx, xxxxxxx xxxxxxx, xxxxxxxxxxxxx xxxxxxxx nebo xxxxxxxxxxx xxxx xxxxxxxxx xxxxxx.

X3. XXXX2- XXXXXXXX

Xxxxxxx xxxxxxxxxx x xxxxxxxxxxxx xxxx-2 agonisté, včetně xxxxx xxxxxxxxx isomerů, xxxx zakázáni.

Zahrnují (ale xx x xxxxxxxx xxxxx xx ně):

Fenoterol; xxxxxxxxxx; xxxxxxxxx; xxxxxxxxxxx; xxxxxxxxxx; xxxxxxxxxx; reproterol; xxxxxxxxxx; xxxxxxxxxx; terbutalin; xxxxxxxxxxx; vilanterol.

Výjimkou jsou:

• inhalační xxxxxxxxxx: maximálně 1600 xxxxxxxxxx xx 24 xxxxx x xxxxxxxxxx xxxxxxx, xxxxxxxxxxxxxxxx 800 xxxxxxxxxx během xxxxxxx 12 xxxxx xx xxxxxxxxx xxxxx;
• xxxxxxxxx xxxxxxxxxx: xxxxxxxxx xxxxxx xxxxx 54 xxxxxxxxxx xx 24 hodin;
• inhalační xxxxxxxxxx: xxxxxxxxx 200 xxxxxxxxxx xx 24 xxxxx.

Xxxxxxxxxx xxxxxxxxxxx x moči x xxxxxxxxxxx xxxxx xxx 1000 ng/ml x xxxxxxxxxx xxxxxxxxxxx x xxxx x xxxxxxxxxxx xxxxx než 40 ng/ml xxxxxx xxxxxxxxxx xx zamýšlené xxxxxxxxxxxx xxxxxxx, xxx xxxx považována xx xxxxxxxxx xxxxxxxxxxx nález, xxxxx xxxxxxxxx neprokáže xxxxxxxxxxxxx xxxxxxxxxxxxxxxxx xxxxxx, xx abnormální výsledek xxx způsoben xxxxxxxxxxxxx xxxxxx (x xxxxxxxx) xxxxx, xxx výše xxxxxxx xxxxxxxxx xxxxx.

X4. XXXXXXXXX X XXXXXXXXXXX XXXXXXXXXX

Xxxxxxxx xxxx xxxxxxxxxxx xxxxxxxxx x xxxxxxxxxxx xxxxxxxxxx:

1. Inhibitory xxxxxxxx, xxxxxxxxxx:

Xxxxxxxxxxxxxxxx;

xxxxxxxxxx;

xxxxxxxx-1,4,6-xxxxx-3-17-xxxx (xxxxxxxxxxxxxxxxx);

xxxxxxxx-3,5-xxxx-7-17-xxxx (arimistan);

4-androsten-3,6,17-trion (6-xxx);

xxxxxxxxx;

xxxxxxxxx;

xxxxxxxx;

xxxxxxxxxxx, ale xx x xxxxxxxx xxxxx xx ně.

2. Selektivní xxxxxxxxxx estrogenových xxxxxxxxx (XXXX), xxxxxxxxxx:

Xxxxxxxxx;

xxxxxxxxx;

xxxxxxxxx, xxx xx s xxxxxxxx xxxxx xx xx.

3. Xxxxxxx xxxxxxxxxxxxxx xxxxx xxxxxxxxxx:

Xxxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxx, xxx xx x omezením xxxxx xx xx.

4. Xxxxx modifikující xxxxxx(x) xxxxxxxxxx xxxxxx inhibitorů xxxxxxxxxx, xxx ne x xxxxxxxx pouze xx ně.

5. Xxxxxxxxxxx xxxxxxxxxx:

5.1 Aktivátory XXX-xxxxxxxxxx xxxxxxxxxxxxx (XXXX), např. XXXXX; x Xxxxxxxx Xxxxxxxxx xxxxx xxxxxxxxxxxx xxxxxxxxxxxxxx proliferátory (XXXXδ), xxxx. 2-(2-xxxxxx-4-((4-xxxxxx-2-(4-(xxxxxxxxxxxxxxx)xxxxxx)xxxxxxx-5-xx)xxxxxxxxxx)xxxxxxx) xxxxxxxx xxxxxx (XX1516, XX501516);

5.2 xxxxxxxx x mimetika xxxxxxxx;

5.3 xxxxxxxxx;

5.4 xxxxxxxxxxxx.

X5. XXXXXXXXX X MASKOVACÍ XXXXX

Xxxxxxxxxxx xxxxxxxxx x xxxxxxxxx xxxxx xxxx xxxxxxxx, xxxxxx xxxx xxxxx xxxxx s xxxxxxxx xxxxxxxxx strukturou x xxxxxxxxx xxxxxxxxxxxx xxxxxx.

Xxxxxxxx:

• Xxxxxxxxxxxx; plasmaexpandery (např. xxxxxxxxxx podání xxxxxxxx, xxxxxxxx, xxxxxxxxxxxxxxxxxx a xxxxxxxxx); xxxxxxxxxx, ale xx x xxxxxxxx xxxxx na ně.

• Acetazolamid; xxxxxxxx; xxxxxxxxx; xxxxxxxxx; xxxxxxxxxxxx; indapamid; xxxxxxxx; xxxxxxxx xxxxxxxxxx; xxxxxxxxx; xxxxxxxxxxxxx; xxxxxxxx (např. xxxxxxxxxxxxxxxxxx, xxxxxxxxxxxxxxxxxx, chlorothiazid); xxxxxxxxxx x xxxxxxx (xxxx. tolvaptan), ale xx s xxxxxxxx xxxxx xx xx.

X xxxxxxxx:

• xxxxxxxxxxxx; xxxxxxxxx x xxxxxx xxxxxx xxxxxxxxxx xxxxxxxxxxxxxx (xxxx. xxxxxxxxxxx x brinzolamidu)

• Lokálního podání xxxxxxxxxxxx xxx zubní xxxxxxxxx

Xxxxx jakéhokoliv xxxxxxxx xxxxx xx stanoveným xxxxxxxx limitem (xx. xxxxxxxxxx, xxxxxxxxxx, xxxxx, xxxxxxx, xxxxxxxxxxxx x xxxxxxxxxxxxx) xx Xxxxxx Xxxxxxxxx kdykoliv xxxx xxxxxxxx Při Soutěži xx xxxxxxx x xxxxxxxxxx xxxx jinou xxxxxxxxx xxxxxx, xxxx xxxxxxxxxx za Pozitivní xxxxxxxxxxx nález, pokud Xxxxxxxxx nemá xxxxxxxxxx Xxxxxxxxxxxxx xxxxxxx (TV) xx tuto xxxxx xxxxx k xx, xxxxx xxx byla xxxxxxx xx xxxxxxxxxx xxxx xxxxx maskovací xxxxx.

XXXXXXXX METODY

M1. XXXXXXXXXX X XXXX X XXXXXXXX XXXXXXXXXXXX

Xxxxxxxx xx xxxxxxxxxxx:

1. Xxxxxx nebo xxxxxxxxxxxxx xxxxxxxxxxx xxxxxxxx xxxxxxxxx, xxxxxxxx (homologní) xxxx xxxxxxxxxxx xxxx xxxx xxxxxxxxx xxxxxxx x xxx xxxxxxxxx xxxxxxxx jakéhokoliv původu xx xxxxxxxxx xxxxxxx.

2. Xxxxx xxxxxxxxx xxxxxxxx, xxxxxxx xxxx xxxxxxx xxxxxxx.

Xxxxxxxxxx:

xxxxxxxxxxxx hemoglobinové xxxxxxxx (xxxx. krevní náhražky xxxxxxxx na xxxxxxxxxxx x mikroenkapsulované xxxxxxxxxxx), xxxxxxxxxxxxxxxxxxx a xxxxxxxxxxx (XXX13), ale ne x xxxxxxxx xxxxx xx xx. Inhalační xxxxxxxxxxxx kyslíkem zakázána xxxx.

3. Xxxxxxxxx forma xxxxxxxxxxxxxxx xxxxxxxxxx s xxxx xxxx x xxxxxxxx komponentami xxxxxxxxxxx xxxx chemickými xxxxxxx.

X2. XXXXXXXX X FYZIKÁLNÍ XXXXXXXXXX

Xxxxxxxx xx následující:

1. Xxxxxxxxx, nebo Xxxxx x Podvod, xx xxxxxx xxxxxxx xxxxxxxxx x xxxxxxxx Xxxxxx xxxxxxxxxx xxx Xxxxxxxxx xxxxxxxx. To zahrnuje xxxxxx x/xxxx xxxxxx (xxxx. xxxxxxxxxx) xxxx, xxx xx s xxxxxxxx pouze xx xx.

2. Xxxxxxxxxx infuze x/xxxx xxxxxxx více xxx xxxxxx 100 xx xx 12 xxxxx xxxxx xxxxxx xxxxxxxxx přijatých x xxxxxxx xxxxxxxxxxxx xxxxxxx, xxxxxxxxxxxxx xxxxxxx nebo xxxxxxxxxx diagnostických metod.

M3. XXXXXX DOPING

Z důvodu xxxxxxxxxx xx xxxxxxx xxxxxxxxxxx xxxxxx xx xxxxxxxx xxxxxxxxxxx:

1. Xxxxxxx xxxxxxxx xxxxxxxxxx kyselin xxxx jejich xxxxxxx;

2. Xxxxxxx xxxxxxxxx xxxxxxxxxxxxx xxxxxxxxx, vytvořených x xxxxxxxxxxx sekvencí xxxxxx x/xxxx k transkripční xxxx xxxxxxxxxxxx xxxxxxxx xxxxxx xxxxxxx.

3. Použití xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxxxx xxxxx;

XXXXX X XXXXXX XXXXXXXX XXX XXXXXXX

Xxxxx xxxxxxxxx S0 xx X5 x X1 až X3 xxxxxxxxx výše

jsou Xxx Xxxxxxx zakázané i xxxxxxxxxxx xxxxxxx:

XXXXXXXX XXXXX

X6. XXXXXXXXXXX

Xxxxxxx xxxxxxxxxxx včetně xxxxx xxxxxx xxxxxxxxxx xxxxxxxxx isomerů, xxxx. x- a X-, xxxx xxxxxxxx.

Xxxxxxxxxxx zahrnují:

(a) Xxxxxxxxxxxx stimulancia:

Adrafinil;

amfepramon;

amfetamin;

amfetaminil;

amifenazol;

benfluorex;

benzylpiperazin;

bromantan;

fendimetrazin;

fenetylin;

fenfluramin;

fenkamin;

fenproporex;

fentermin;

fonturacetam /4-fenylpiracetam (xxxxxxxx)/;

xxxxxxxxxx;

xxxxxxxxxxx;

xxxxxx;

xxxxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxxxxxxxx;

xxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxxxxx (x-);

xxxxxxxx;

xxxxxxxxx;

xxxxxxxxxxxxxx;

x-xxxxxxxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxx.

Xxxxxxxxxxxx, které xxxx výslovně uvedeno x xxxxx xxxxxxxx, xx Xxxxxxxxxxx xxxxxx.

(x) Xxxxxxxxxx xxxxxxxxxxx.

Xxxxxxxx (xxx xx x xxxxxxxx xxxxx xx xx):

Xxxxxxxxx (xxxxxxxxx)****;

xxxxxxxxxxx;

xxxxxxxxxxxxxxxxx;

1,3-xxxxxxxxxxxxxxxx;

xxxxxxx***;

xxxxxxxx;

xxxxxxxxxxxxx;

xxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxxxx a jeho xxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxxxxxxxxx (xxxxxxxxxxxxxxxxxxxx);

xxxxxxxxxxxx;

xxxxx**;

xxxxxxx a xxxx xxxxxxx (např. xxxxxxxx, xxxxxxxxx x xxxx-xxxxxxxxxxxxxxxxxxxxx);

xxxxxxxxxxxxxxx;

xxxxxxxxxxxx;

xxxxxxxxxxxx***;

xxxxxxxxxxxxxxxxxxxxxxxx;

xxxxxxxxxxxx;

4-xxxxxxxxxx-2-xxxx (xxxxxxxxxxxxxx);

xxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxx;

xxxxxxxxx (xxxxxxxxxxxxx);

xxxxxxx;

xxxxxxxxxxx;

xxxxxxxxxxxxxx;

xxxxxxxxxxxxx*****;

xxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxx;

xxxxxxxxxxxx (xxxxxxxxxxxxxxxxxxxxx);

xxxxxxxxxxxxx

x další xxxxx x podobnou xxxxxxxxx xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxx xxxxxx.

X výjimkou:

• klonidinu

• derivátů xxxxxxxxx x xxxxxxx xxxxxx xxxxxxxx/xxxxxx xxxxxxx x stimulancií xxxxxxxxxx xx Monitorovacího programu xxx xxx 2018*.

* Xxxxxxxxx, fenylefrin, xxxxxxxxxxxxxxxxx, xxxxxx, xxxxxxx, xxxxxxxxx x synefrin: Xxxx xxxxx jsou xxxxxxxx xx Monitorovacího xxxxxxxx 2018 a nejsou xxxxxxxxxx xx Xxxxxxxx xxxxx.

** Xxxxx: xx xxxxxxxx pouze xxx xxxxxxxxxxx xxxxx xxx 5 xxxxxxxxxx x 1 xx moči.

*** Xxxxxxx x xxxxxxxxxxxxx: xxxx zakázány xxx xxxxxxxxxxx xxxxx xxx 10 mikrogramů x 1 ml xxxx.

**** Xxxxxxxxx (xxxxxxxxx): xxxx xxxxxxx při xxxxxxxx xxxxxx, xxxx. xxxxx, xxxx aplikace xxxx xxxx xxxxxx xxxxxxxx x lokálními xxxxxxxxxx.

***** Xxxxxxxxxxxxx: xx xxxxxxx, xxxxx xxxx xxxxxxxxxxx x moči xx xxxxx xxx 150 xxxxxxxxxx na xxxxxxxx.

X7. XXXXXXXXX

Xxxxxxxxxxx narkotika xxxx xxxxxxxx:

Xxxxxxxxxxx;

xxxxxxxxxxxxx;

xxxxxxxxx(xxxxxx);

xxxxxxxx a xxxx xxxxxxxx;

xxxxxxxxxxx;

xxxxxxx;

xxxxxx;

xxxxxxxxxx;

xxxxxxxx;

xxxxxxxxx;

xxxxxxxxxx;

xxxxxxx.

X8. XXXXXXXXXXX

Xxxxxxxxxxx xxxxxxxxxxx xxxx xxxxxxxx:

• Xxxxxxxx kanabinoidy, xxxx. hašiš, xxxxxx x xxxxxxxxx.

• Xxxxxxxxxx xxxxxxxxxxx, xxxx. delta9-tetrahydrokanabinol (XXX) x ostatní xxxxxxxxxxxxxx.

Xxxxx: xxxxxxxxxxxx

X9. XXXXXXXXXXXXXXX

Xxxxxxx xxxxxxxxxxxxxxx xxxxxxxx xxxxxx, xxxxxxxx, xxxxxxxxxx xxxx nitrosvalovou xxxxxxxx jsou zakázané.

Včetně, xxx xx x xxxxxxxx xxxxx xx xx:

xxxxxxxxxxx;

xxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxxxxxx;

xxxxxxxx;

xxxxxxxxxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxx;

xxxxxxxxxxxx.

XXXXX ZAKÁZANÉ X&xxxx;XXXXXXXX XXXXXXXX

X1. BETA-BLOKÁTORY

Beta-blokátory xxxx xxxxxxxx xxxxx x xxxxxxxxxxxxx xxxxxxxx Xxx Xxxxxxx, a kde xx to xxxxxxxx x Xxxx soutěž.

• Automobilový xxxxx (FIA)

• Billiard (xxxxxxx xxxxxxxxxx) (WCBS)

• Golf (XXX)

• Xxxxxxxxxxx (XX)*

• Xxxxxxxx (XXX) - xxxxx na lyžích x xxxxxxxxxxx lyžování-skoky x U-rampa, x xxxxxxxxx U-rampa x "xxx air"

• Podvodní xxxxxx (xxxxxxxxx xxxxxxxx) (CMAS) x disciplínách xxxxxxxxxx xxxx x xxxxxxxxx xxxx bez ploutví, xxxxxxxxx apnoe s xxxxxxxxx xxxx bez xxxxxxx, free xxxxxxxxx, xxxx blue, spearfishing, xxxxxxxx apnoe, střelba xxxxxxxx xx xxxx x xxxxxxxxxx váha.

• Střelba (XXXX, XXX)*

• Xxxxx (WDF)

* Xxxxxxxx xxxx Xxxx xxxxxx

Xxxx-xxxxxxxxx xxxxxxxx xxxxxxxxxxx xxxxx:

Xxxxxxxxxx;

xxxxxxxxxx;

xxxxxxxx;

xxxxxxxxx;

xxxxxxxxxx;

xxxxxxx;

xxxxxxxxxx;

xxxxxxx;

xxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxxxxx;

xxxxxxxxxx;

xxxxxxx;

xxxxxxxxxx;

xxxxxxxx;

xxxxxxxxxxx;

xxxxxxx;

xxxxxxx;

xxx xx x xxxxxxxx xxxxx xx xx.

Xxxxxxxxx

Xxxxxx předpis x. 36/2019 Xx. x. x. xxxxx xxxxxxxxx xxxx 26.7.2019.

Právní předpis x. 36/2019 Sb. x. x. xxx xxxxxx xxxxxxx předpisem č. 32/2023 Sb. m. s. x xxxxxxxxx xx 22.8.2023.

Xxxxx xxxxxxxxxxxx xxxxxxxx norem xxxxxx xxxxxxxx xxxxxxxx x xxxxxxxx xxxx xxxxxxxxxxxxx, xxxxx se xxxx xxxxxx derogační změna xxxxx xxxxxxxxx xxxxxxxx xxxxxxxx.

1) Mezinárodní xxxxxx xxxxx dopingu ve xxxxxx, xxxxxxx xxx 19. října 2005 x Xxxxxx, xxxx xxxxxxxxx x xxxxxxxxx xxxxx a x xxxxxxxxx xx xxxxxxx xxxxxx xxx č. 58/2007 Sb. m. s.

Xxxx xxxxx xxxxxxxx Xxxxxx xx xxxxxxx xxxxxx xxxx xxxxxxxxx pod č. 46/2008 Sb. m. s.